Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Table A. SARS-CoV-2 Variants Currently or Recently Circulating in the United States and Their Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies

Last Updated: March 6, 2023

See the Guidelines Archive for information on bamlanivimab plus etesevimab, casirivimab plus imdevimab, and variants that were previously circulating in the United States.

Table A. SARS-CoV-2 Variants Currently or Recently Circulating in the United States and Their Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
WHO Label and Pango LineageBEBTIX Plus CILSOT
In Vitro SusceptibilityaAnticipated Clinical ActivityIn Vitro SusceptibilityaAnticipated Clinical ActivityIn Vitro SusceptibilityaAnticipated Clinical Activity
Omicron BA.5No changeActiveModerate reductionActiveMarked reductionUnlikely to be active
Omicron BA.4.6/BF.7 No changeActiveMarked reductionUnlikely to be activeMarked reductionUnlikely to be active
Omicron BQ.1Marked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be active
Omicron BQ.1.1Marked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be active
Omicron XBBMarked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be active
Omicron XBB.1.5Marked reductionUnlikely to be activeMarked reductionUnlikely to be activeMarked reductionUnlikely to be active

References

  1. Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization (EUA) of sotrovimab. 2022. Available at: https://www.fda.gov/media/149534/download.
  2. Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). 2023. Available at: https://www.fda.gov/media/154701/download.
  3. Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for bebtelovimab. 2022. Available at: https://www.fda.gov/media/156152/download.
  4. Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388(1):89-91. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36476720.
  5. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279-286.e8. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36580913.
  6. Takashita E, Yamayoshi S, Halfmann P, et al. In vitro efficacy of antiviral agents against Omicron subvariant BA.4.6. N Engl J Med. 2022;387(22):2094-2097. Available at: https://pubmed.ncbi.nlm.nih.gov/36383452/.
  7. Wang Q, Li Z, Ho J, et al. Resistance of SARS-CoV-2 Omicron subvariant BA.4.6. to antibody neutralisation. Lancet Infect Dis. 2022;22(12):1666-1668. Available at: https://pubmed.ncbi.nlm.nih.gov/36328002/.
  8. Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387(5):468-470. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35857646.
  9. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608(7923):603-608. Available at: https://pubmed.ncbi.nlm.nih.gov/35790190/.